Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine

Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine

A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino-pentofuranosyl)-N4- palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltran...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: FLEMING, IAN NEIL, GREEN, SIMON RICHARD, MACKAY, RUTH
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator FLEMING, IAN NEIL
GREEN, SIMON RICHARD
MACKAY, RUTH
description A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino-pentofuranosyl)-N4- palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2009259136BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2009259136BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2009259136BB23</originalsourceid><addsrcrecordid>eNqNjbEOgkAQRGksjPoPW9CaIEQTSjg0VlRakwWW3Ea4I7drjH8vhbG2mszL5M06ehg_texQ2TsBP4DgjB0rLpDABzB1VRh4sVqo6gImUvseNaCTgQIKATvLLasPAvLsLKBATz8Duh7m4DtcyjZaDTgK7b65ieLL-Waue5p9Q7L8kiNtinuaJHl6zA_ZqSzT7M_ZBwI5Qj0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine</title><source>esp@cenet</source><creator>FLEMING, IAN NEIL ; GREEN, SIMON RICHARD ; MACKAY, RUTH</creator><creatorcontrib>FLEMING, IAN NEIL ; GREEN, SIMON RICHARD ; MACKAY, RUTH</creatorcontrib><description>A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino-pentofuranosyl)-N4- palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140925&amp;DB=EPODOC&amp;CC=AU&amp;NR=2009259136B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140925&amp;DB=EPODOC&amp;CC=AU&amp;NR=2009259136B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FLEMING, IAN NEIL</creatorcontrib><creatorcontrib>GREEN, SIMON RICHARD</creatorcontrib><creatorcontrib>MACKAY, RUTH</creatorcontrib><title>Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine</title><description>A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino-pentofuranosyl)-N4- palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjbEOgkAQRGksjPoPW9CaIEQTSjg0VlRakwWW3Ea4I7drjH8vhbG2mszL5M06ehg_texQ2TsBP4DgjB0rLpDABzB1VRh4sVqo6gImUvseNaCTgQIKATvLLasPAvLsLKBATz8Duh7m4DtcyjZaDTgK7b65ieLL-Waue5p9Q7L8kiNtinuaJHl6zA_ZqSzT7M_ZBwI5Qj0</recordid><startdate>20140925</startdate><enddate>20140925</enddate><creator>FLEMING, IAN NEIL</creator><creator>GREEN, SIMON RICHARD</creator><creator>MACKAY, RUTH</creator><scope>EVB</scope></search><sort><creationdate>20140925</creationdate><title>Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine</title><author>FLEMING, IAN NEIL ; GREEN, SIMON RICHARD ; MACKAY, RUTH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2009259136BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2014</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>FLEMING, IAN NEIL</creatorcontrib><creatorcontrib>GREEN, SIMON RICHARD</creatorcontrib><creatorcontrib>MACKAY, RUTH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FLEMING, IAN NEIL</au><au>GREEN, SIMON RICHARD</au><au>MACKAY, RUTH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine</title><date>2014-09-25</date><risdate>2014</risdate><abstract>A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino-pentofuranosyl)-N4- palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy- -D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2009259136BB2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A58%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FLEMING,%20IAN%20NEIL&rft.date=2014-09-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2009259136BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true